Stock SEEL SEELOS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Seelos Therapeutics, Inc.

Equities

SEEL

US81577F2083

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.291 USD +1.89% Intraday chart for Seelos Therapeutics, Inc. -13.00% -79.06%
Mar. 19 Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected MT
Mar. 19 Seelos Therapeutics' ALS treatment fails in mid-stage study RE

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
PR
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
AQ
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
PR
Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration
AQ
Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002
PR
Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote 'FOR' All Proxy Proposals at the Special Meeting to be held on January 10, 2024
AQ
Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024
PR
Seelos Therapeutics, Inc. Releases Letter to its Stockholders
PR
Seelos Therapeutics Announces the Selection of SLS-002 for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder
AQ
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split
AQ
Seelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder (PTSD)
PR
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split
PR
Seelos: Q3 Earnings Snapshot
AQ
Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's disease at Neuroscience 2023
AQ
Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023
PR
Seelos Therapeutics Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborations
PR
Seelos Therapeutics : Material Agreement - Form 8-K
PU
Seelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease
PR
Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock
PR
Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SEEL Stock
  4. News Seelos Therapeutics, Inc.
  5. Press Releases